Navigation
banner

Genomics & Big Data Summit

2018-04-232018-04-262018-03-07
EARLY BIRD DISCOUNT! Register by Apr 26, 2018 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Pamila Brar

Pamila Brar
Medical Director, Heath Nucleus
Health Nucleus/Human Longevity, Inc.
Pamila Brar
Medical Director, Heath Nucleus
Health Nucleus/Human Longevity, Inc.
 
About Speaker:

Dr. Pamila Brar joined the HLI team in July 2015 as Medical Director of the Health Nucleus. Pam graduated from LSU Medical School in 1995 at age 23, and moved to San Diego to complete her Internal Medicine training. She was awarded the title of Ellen Browning Scripps Chief Medical Resident at Scripps Clinic La Jolla in 1999. After serving several years as a Scripps Clinic concierge physician, she started her own concierge medical practice in La Jolla in 2009 where she thrived.

Active in the American Academy of Private Physicians, a national organization dedicated to private medicine and healthcare innovation, Pam became an AAPP conference speaker, board member, and then served as the organization’s president from April 2015 to 2017. In recent years, Pam appeared regularly as a health consultant on San Diego news stations and honed her skills in communication. Despite her success in private practice, Pam’s love for science led her to join HLI in May 2015 as Medical Director of the Health Nucleus. This endeavor has allowed her to leverage her private medicine, leadership and business modeling experience to collaboratively grow a disruptive health intelligence delivery model. Utilizing whole genome sequencing, advanced imaging and omics, the Health Nucleus is a pioneer in the field of early detection and personalized medicine. The opportunity to collaborate with scientific visionaries including Craig Venter and Karen Nelson has been among the highlights of Pam’s career.

Howard Federoff

Howard Federoff
Professor of Neurology
University of California, Irvine
Howard Federoff
Professor of Neurology
University of California, Irvine
 
About Speaker:

Howard Federoff, M.D., Ph.D., is the former CEO of the UCI Health System and Vice Chancellor for Health Affairs after previously serving as the Dean of the School of Medicine. Dr. Federoff led alignment between both clinical expansion and the expansion of our academic and research missions. Dr. Federoff oversaw the creation of the Susan Samueli Institute for Integrative Health, the Medical Innovation Institute, the Center for Precision and Population Health and the co-founded the Institute for Future Health with Bren Professor Ramesh Jain. A nationally renowned clinical and research leader and a groundbreaking investigator for neurological disorders, Dr. Federoff's research led to a new gene therapeutic trial in Parkinson's disease, in predicting the onset of Alzheimer's disease. Dr. Federoff has an academic appointment in the department of Neurology. He has published greater than 250 peer reviewed and invited articles and serves as a reviewer for many journals, and currently serves on the editorial boards of five journals. Dr. Federoff served as Chair of the NIH Recombinant DNA Advisory Committee from 2007-2010. He Chaired the Gene Therapy Resource Program for NHLBI (2010-2016), was President for the American Society for Neural Therapy and Repair (2012-2013) and President of the American Society for Experimental Neurotherapeutics (2014-2016). He is chair-elect of the Association of Academic Health Centers (AAHC) Board. Dr. Federoff is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Inventors.

Eugene Koonin

Eugene Koonin
Senior Investigator
National Center for Biotechnology Information, NIH
Eugene Koonin
Senior Investigator
National Center for Biotechnology Information, NIH
 
About Speaker:

Eugene V. Koonin. Education: BSc, Moscow State University, Russia; PhD, Moscow State University, Russia; Postdoctoral Fellow, Institute of Poliomyelitis, Russian Academy of Medical Sciences. Present position: Leader of Evolutionary Genomics Group, Senior Investigator, National Center for Biotechnology Information, NIH. Honors and awards: Fellow, AAM; Fellow, American Academy of Arts and Sciences; Member, National Academy of Sciences of the USA; Foreign Associate, European Molecular Biology Organization; Doctor Honoris Causa, Universite Aix-Marseille (France), Wageningen University (Netherlands); National Library of Medicine Board of Regents Award; NIH Director’s Award. Professional activities: Editor-in-Chief, Biology Direct; Section editor, Trends in Genetics; Associate Editor: Genome Biology and Evolution; Editorial Boards: Nucleic Acids Research, BMC Biology.

Christina Waters

Christina Waters
Senior Vice President
WuXi NextCODE
Christina Waters
Senior Vice President
WuXi NextCODE
 
About Speaker:

Dr. Christina Waters’ broad range of experience in leading medical research in both biotech/large pharmaceutical companies to non-profits converge to specialize in new approaches to personalized medicine and implementation of new innovative research initiatives to accelerate treatments to patients.

She serves as SVP and GM of the Global Rare Disease Program at WuXi NextCODE and Founder/CEO of RARE Science, a non-profit research organization that accelerates discovery of therapeutic solutions for kids with rare disease.  She serves as a Scientific Advisory board member, for Global Genes, which focuses on rare disease advocacy.

Dr. Waters received her Ph.D. in Genetics from UC Davis and was a Postdoctoral Scholar and Associate of the Howard Hughes Medical Institute, California Institute of Technology.  Dr. Waters completed an NIH Postdoctoral fellowship at University of California, Berkeley, and received a BS degree from San Diego State University. Dr. Waters received her MBA from UCLA. 

PLENARY SPEAKERS
Shawn Baker

Shawn Baker
Genomics Advisor/Consultant
SanDiegOmics.com
Shawn Baker
Genomics Advisor/Consultant
SanDiegOmics.com
 
About Speaker:

Shawn Baker has over 20 years experience in the field of genomics, with an extensive and broad background in the industry, ranging from R&D, product development, marketing, and business and scientific consulting. After receiving his Ph.D. from the University of California – Davis, he joined Illumina as a research scientist when it was a 15-person startup, later transitioning into market management, leading the team responsible for gene expression and regulation. He is the co-founder and CSO of AllSeq, an online sequencing marketplace, which offers a unique and unbiased perspective on the consumer and technology trends in the genomics market. Through his consultancy business at SanDiegOmics.com, he serves as an advisor to startups in the genomics space and helps educate the financial community on next generation sequencing and its impact on diagnostics and healthcare.

Karen Keeley

Karen Keeley
Patient Advocate/Biotechnology
Agility Clinical/Precision for Medicine
Karen Keeley
Patient Advocate/Biotechnology
Agility Clinical/Precision for Medicine
 
About Speaker:

Karen is a Biotechnology Consultant working with several Biotech companies in San Diego and abroad. Focusing primarily on Biotech Startup Project Management activities: Business Development, Patient Engagement, Education, Devices and digital healthcare, Rare and Orphan Clinical Trial activities and promotion and recruitment via website development and social media marketing strategy. Notable is her 17 years of experience in the Autism/A.D.D./I.E.P. Education and Medical Advocacy and Records space and more recently the Genetic testing and block chain ecosystem.

Jeffery Schloss

Jeffery Schloss
Former Director, Division of Genome Sciences, NHGRI, NIH
Independent Scientist
Jeffery Schloss
Former Director, Division of Genome Sciences, NHGRI, NIH
Independent Scientist
 
About Speaker:

Jeffery A. Schloss, Ph.D., is experienced in running programs to develop and implement genomic technologies. He was most recently Director, Division of Genome Sciences, Extramural Research Program, National Human Genome Research Institute (NHGRI), U.S. National Institutes of Health, where he supervised the scientists who were responsible for well-known, productive programs such as NHGRI’s Genome Sequencing Program, ENCODE, 1000 Genomes, $1,000 Genome Technology program, and much of NHGRI’s informatics program, and NIH Common Fund programs including KOMP, LINCS, H3Africa, Protein Capture, and the Human Microbiome Program. Earlier, as a Program Director at NHGRI, Schloss developed and implemented the program to develop technologies to sequence human genomes at a cost of $1,000, and the Centers of Excellence in Genomic Science; in the early days of the Human Genome Project he managed grants to centers that were building human and model organism physical and genetic maps, and helped initiate the scale-up to HGP sequencing. Schloss served on numerous trans-NIH and trans-federal-agency programs including the NIH Bioengineering Consortium and the National Nanotechnology Initiative. He was on the biology faculty at the University of Kentucky after a postdoc in the biology department at Yale University and earning the PhD degree in cell biology at Carnegie Mellon University.

David Scott

David Scott
Co-Founder
Arbor Biotechnologies
David Scott
Co-Founder
Arbor Biotechnologies
 
About Speaker:

David works at the intersection of computer science and biology, leveraging emerging data streams to create exciting new biotechnologies. Prior to co-founding Arbor, David completed his PhD in the laboratory of Feng Zhang at MIT and the Broad Institute, where he contributed to the early development of CRISPR-Cas systems for mammalian genome editing applications. As part of this work, David created experimental and computational techniques to enhance the precision of CRISPR-Cas applications and discover novel CRISPR gene editing systems. David is the recipient of the National Science Foundation Graduate Research Fellowship, the Henry E. Singleton Fellowship, and the Angus MacDonald Award for Excellence in Undergraduate Teaching. He received his BS in Cognitive Science from the University of California San Diego, where he co-authored several research studies illuminating the early progression of Alzheimer’s and Parkinson’s diseases.

Salik Syed

Salik Syed
CEO
VALIS Software Corp.
Salik Syed
CEO
VALIS Software Corp.
 
About Speaker:

Salik is the CEO of VALIS, a cloud-based data infrastructure platform for genomics. Salik is a serial entrepreneur in the data analytics and visualization space -- his last company, Parastructure, was acquired by Dropbox in 2014.

CRISPR & Genome Engineering
DISTINGUISHED SPEAKERS
Leonela Amoasii

Leonela Amoasii
Director of Research
Exonics Therapeutics
Leonela Amoasii
Director of Research
Exonics Therapeutics
 
About Speaker:

Dr. Leonela Amoasii works in the laboratory of Dr. Eric Olson at the University of Texas Southwestern Medical Center in Dallas. Dr. Amoasii pursued her graduate studies at the Institut de Genetique Biologie Moléculaire et Cellulaire (IGBMC) at the University of Strasbourg in France. During her doctoral studies, she uncovered the mechanistic basis of myotubular centronuclear myopathy and acquired expertise in the use of adeno-associated virus (AAV) for manipulation of gene expression in muscle. Over the last years Dr. Amoasii has been involved in developing a new therapeutic approach for correction of Duchenne muscular dystrophy using CRISPR/Cas9 genomic editing. Dr. Amoasii pursued the in vivo optimization of the CRISPR/Cas9 genomic editing, her recent work reveals promising results for translation of the genome editing technology to human patients.

Ethan Bier

Ethan Bier
Professor
University of California, San Diego
Ethan Bier
Professor
University of California, San Diego
 
About Speaker:
Benjamin Borgo

Benjamin Borgo
Senior Product Manager, Genome Editing
Agilent
Benjamin Borgo
Senior Product Manager, Genome Editing
Agilent
 
About Speaker:

Ben has been at Agilent for 3 years managing product portfolios in diagnostics and genomics. His first exposure to CRISPR was as a graduate student where he attempted to engineer split variants of the Cas9 nuclease. Though he met with little success, it inspired a passion for the technology which he has brought with him to Agilent. Prior to joining Agilent, he worked on several start-up companies focused on software and nanopore-based molecular diagnostics. Ben has a PhD and MBA from Washington University in St. Louis.

Kristopher Brannan

Kristopher Brannan
Postdoctoral Fellow, Cellular and Molecular Medicine
University of California, San Diego
Kristopher Brannan
Postdoctoral Fellow, Cellular and Molecular Medicine
University of California, San Diego
 
About Speaker:

In 2014 Kristopher began his postdoctoral research with the Yeo lab, focusing on protein-protein and protein-RNA interactions important for controlling mRNA fate in the context of neuronal development and neurodegenerative disease.

Peter Cameron

Peter Cameron
Group Leader, Technology Development
Caribou Biosciences
Peter Cameron
Group Leader, Technology Development
Caribou Biosciences
 
About Speaker:

Peter Cameron earned his Bachelors of Science from the University of Wisconsin-Madison and a PhD in Molecular and Cellular Biology from the University of California-Berkeley. During his graduate work, he investigated the molecular and cellular biology underlying taste detection in the fruit fly. After graduating, he performed postdoctoral work at The Scripps Research Institute in San Diego, where he developed novel genetic tools to manipulate neural circuits in the mouse brain that underly innate behaviors such as aggression and fear. Following that, Peter was hired as a Scientist at Caribou Biosciences, where he worked on a comprehensive, genome-wide method to measure CRISPR-Cas9 specificity. This method, termed SITE-Seq, was recently published in the May, 2017 issue of Nature Methods. Peter now heads the Technology Development group at Caribou Biosciences, where he leads efforts to develop novel tools and technologies for precision genome editing.

Mark Kay

Mark Kay
Dennis Farrey Family Professor, Departments of Pediatrics and Genetics
Stanford University
Mark Kay
Dennis Farrey Family Professor, Departments of Pediatrics and Genetics
Stanford University
 
About Speaker:

Dr. Kay is the Head of the Division of Human Gene Therapy and the Dennis Farrey Family Professor in the Departments of Pediatrics and Genetics at Stanford University. He received a Ph.D. in Developmental Genetics, and M.D. from Case Western Reserve in Cleveland, Ohio.  Before coming to Stanford in 1998, Dr. Kay was at the University of Washington as Associate Professor in the Departments of Medicine, Biochemistry and Pathology.  Dr. Kay has received many awards.  Dr. Kay was on the founding board of directors of the American Society for Gene Therapy and served as the Society’s Vice-President, President-Elect, and President in 2003-2006. He has served on the Oligonucleotide Therapeutics Board of Directors during the last 5 years.  He was elected to the Association of American Physicians in 2010.  Dr. Kay received the American Society for Gene and Cell Therapy’s Outstanding Investigator Award in 2013. He was awarded the 2017 Distinguished Alumni Award and Commencement Speaker at Lyman Briggs College, Michigan State University.

Dr. Kay has published over 250 scientific papers.  The focus of the laboratory is to establish the scientific principles required for gene and nucleic acid transfer for the treatment of genetic and acquired diseases. Dr. Kay has worked on the development  of many DNA gene transfer vectors and the mechanism by which they transduce tissues in mammals.  His group has performed two Phase I/II gene therapy trials for hemophilia B.  His laboratory was the first to establish therapeutic RNAi in whole non-embryonic mammals, and RNAi-mediated inhibition of a human viral pathogen (HBV) in animals.  His work continues towards defining the molecular limits of delivered and expressed RNAi in vivo as well as the mechanisms involved in si/shRNA -mediated gene silencing and the biological mechanisms involved in miRNA-mediated gene repression.  In addition, his laboratory is studying the role that the newly defined small tRNA-derived RNAs play in mammalian gene regulation.  Dr. Kay is a scientific founder of Voyager Therapeutics and a founder of LogicBio Therapeutics.

Shawn McClelland

Shawn McClelland
Global Bioinformatics Manager
Horizon Discovery
Shawn McClelland
Global Bioinformatics Manager
Horizon Discovery
 
About Speaker:

Responsible for creating and leading Horizon Discovery's Global Bioinformatics team. Supporting bioinformatics and data science activities across all the business sites; supporting products and services including CRISPR gene editing, RNAi, gene modulation, cell lines, and animal models.

Jiwu Wang

Jiwu Wang
President and CEO
Allele Biotechnology
Jiwu Wang
President and CEO
Allele Biotechnology
 
About Speaker:

Dr. Wang is the Founder, President and CEO of Allele Biotechnology & Pharmaceuticals Inc. and the Scintillon Institute for Biomedical and Bioenergy Research. He has been an active researcher in the RNA field for over 20 years with significant contributions to the understanding of RNA-related cellular processes, such as pre-mRNA splicing, RNA interference (RNAi), microRNA (miRNA) in developmental control, and mRNA as a platform for transgenes. His research is the foundation for Allele Biotechnology’s cellular reprogramming platform.

Next Generation Sequencing
DISTINGUISHED SPEAKERS
Serafim Batzoglou

Serafim Batzoglou
VP of Applied and Computational Genomics
Illumina
Serafim Batzoglou
VP of Applied and Computational Genomics
Illumina
 
About Speaker:

Dr. Batzoglou received his PhD in Computer Science from MIT in 2000, joined Stanford University in 2001, where he was a Professor of Computer Science and Biomedical Data Sciences until he joined Illumina at 2016. His work at Stanford and at Illumina has focused on the application of algorithms and machine learning to genome biology and technology.

Kenneth Buetow

Kenneth Buetow
Director, Computational Sciences & Informatics
Arizona State University
Kenneth Buetow
Director, Computational Sciences & Informatics
Arizona State University
 
About Speaker:

Dr. Ken Buetow is a human genetics and genomics researcher who leverages computational tools to understand complex traits such as cancer, liver disease, and obesity. Dr. Buetow currently serves as Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona State University (CAS@ASU), is a professor in the School of Life Sciences in ASU's College of Liberal Arts and Sciences; is a Core Faculty, in ASU’s Center for Evolution and Medicine; and is Director of Bioinformatics and Data Management for the National Biomarker Development Alliance. Dr. Buetow previously served as the founding Director of the Center for Biomedical Informatics and Information Technology within the National Institutes of Health’s National Cancer Institute (NCI).

D. Brian Dawson

D. Brian Dawson
Director, Clinical Laboratories, Division of Human Genetics
Cincinnati Children's Hospital Medical Center
D. Brian Dawson
Director, Clinical Laboratories, Division of Human Genetics
Cincinnati Children's Hospital Medical Center
 
About Speaker:

Director, Clinical Labs, Div Hum Genet, Cincinnati Children's since June 2016; Previously 15 years, Director, Clin MolGen Lab, Mayo Clinic, Rochester; Previous 13 years, Director, MolPath Lab, UT Southwestern, Dallas, TX Main Interest: Developing diagnostic testing for rare, heritable disorders

Andrea Ferreira-Gonzalez

Andrea Ferreira-Gonzalez
Chair of the Division of Molecular Diagnostics in the Department of Pathology; Director of the Molecular Diagnostics Laboratory
Virginia Commonwealth University Health System
Andrea Ferreira-Gonzalez
Chair of the Division of Molecular Diagnostics in the Department of Pathology; Director of the Molecular Diagnostics Laboratory
Virginia Commonwealth University Health System
 
About Speaker:
William Lee

William Lee
Vice President of Bioinformatics
Helix
William Lee
Vice President of Bioinformatics
Helix
 
About Speaker:

Will joined Helix at the beginning and has helped build up their world-class clinical sequencing operation and consumer genomics platform. He trained in Genetics and Computer Science at Stanford, completed his postdoctoral training at Genentech, and was previously leveraging genomic technologies for translational cancer applications and personalized medicine at Memorial Sloan Kettering Cancer Center.

Richard McCombie

Richard McCombie
Professor & Director, The Stanley Institute for Cognitive Genomics
Cold Spring Harbor Laboratory
Richard McCombie
Professor & Director, The Stanley Institute for Cognitive Genomics
Cold Spring Harbor Laboratory
 
About Speaker:
John Thompson (New)

John Thompson
Research and Development
PGDX
John Thompson
Research and Development
PGDX
 
About Speaker:

John Thompson’s career has spanned pharmaceutical, next-gen sequencing, and genetic testing industries. He is currently developing NGS-based clinical diagnostic tests for detecting cancer and its mutational drivers for personalized medicine. Formerly, he served as Chief Technology Officer at Claritas Genomics and improved genetic assays for diagnosing rare pediatric diseases. At Nabsys, he advanced mapping and sequencing of very long DNAs using fully solid-state nanodetectors. Prior to Nabsys, he was Senior Director of Genomic Research at Helicos BioSciences for four years, helping to develop the first commercial single-molecule, next-generation sequencing platform and apply it to a range of DNA and RNA sequencing applications. Before that, his contributions at Pfizer used molecular biology and genetic approaches to identify novel therapeutic targets, to establish the genetic basis of drug response, and to characterize the genetics of drug-induced adverse events.

Big Data Bioinformatics
DISTINGUISHED SPEAKERS
Mark Adams

Mark Adams
Chief Information Officer
Celmatix
Mark Adams
Chief Information Officer
Celmatix
 
About Speaker:

Dr. Adams has been working in bioinformatics and data analytics for more than 20 years, including work in computational biology, biomedicine, intelligence, finance, and biotechnology. Prior to joining Celmatix, he was the Chief Information Officer for the biotechnology company Good Start Genomics. His previous experience includes Bridgewater Associates, Ltd., where he developed unique data warehousing and machine learning approaches to support the world’s largest hedge fund and Booz Allen Hamilton, where as a principal he developed a leading biomedical informatics consulting practice with a primary focus on informatics strategy for clients in the commercial, government, and non-profit markets. Dr. Adams holds a B.A. from Oberlin College and a PhD. from Baylor College of Medicine. He currently lives in Connecticut with his wife and two daughters.

Ram Akella

Ram Akella
Professor
University of California Santa Cruz
Ram Akella
Professor
University of California Santa Cruz
 
About Speaker:
Rick Altinger

Rick Altinger
Chief Executive Officer
Glooko
Rick Altinger
Chief Executive Officer
Glooko
 
About Speaker:

Rick joined Glooko as its first CEO in January 2013 shortly after Glooko received its first FDA clearance. Glooko makes diabetes management easier for patients and their care teams by enabling better and faster data driven decisions that improve outcomes at lower costs.

With 30 years in the technology industry, concentrating on healthcare technology for the last 20 years, Rick has held a variety of leadership positions with large and small organizations in strategy, business development, product management, account management and systems integration positions. He was a Vice President in the healthcare business unit at Intuit where he launched their provider services and drove the effort that resulted in Intuit acquiring Medfusion. Rick was also Executive Vice President at VantageMed, an EHR and billing services company that he helped turnaround and successfully sell. As Vice President of Business Development at Healtheon/WebMD Rick set product strategy and drove major acquisitions including Envoy, Medical Manger, Kinetra and MedE America and played a key role in driving their growth to over $1B in revenue. Rick received a B.S. in mechanical engineering and an M.S. in engineering management from Stanford University.

Amitabha Chaudhuri

Amit Chaudhuri
Vice President of Research and Development
Medgenome
Amit Chaudhuri
Vice President of Research and Development
Medgenome
 
About Speaker:

Dr. Amit Chaudhuri has extensive industrial experience in oncology target discovery and validation from Genentech Inc. and CuraGen Corporation prior to his role as VP, R&D at MedGenome. He has Ph.D. in Biochemistry from Indian Institute of Sciences, Bangalore and did his Postdoctoral research at MGH, Harvard Medical School and at the Department of Molecular and Cellular Biology, Harvard University.

Bin Chen

Bin Chen
Department of Pediatrics and Human Medicine
Michigan State University
Bin Chen
Department of Pediatrics and Human Medicine
Michigan State University
 
About Speaker:

Dr. Bin Chen is an assistant professor in the Institute for Computational Health Sciences at University of California, San Francisco. His lab is moving to Michigan State University in April 2018. Dr. Chen is also the founding member of DahShu, a non-profit organization to promote research and education in data sciences. Dr. Chen trained as a chemist in college, worked as a software engineer before graduate school, trained as a chem/bioinformatician in graduate school, worked as a computational scientist at Novartis, Pfizer and Merck. He received his PhD in informatics at Indiana University, Bloomington and pursed the postdoctoral training in Dr. Atul Butte’s lab at Stanford University. His liver cancer work is recently featured in STAT, GEN, GenomeWeb and KCBS. More info is available on his lab website (http://binchenlab.org/).

Fabricio Costa

Fabricio Costa
Director of Research and Innovation
UCB
Fabricio Costa
Director of Research and Innovation
UCB
 
About Speaker:

I am really passionate about STEM (Science, Technology, Education and Math). My main aim is to positively impact the lives of 7+ billion people in the planet by using my Skills in Technology, Innovation and Research. As a summary of my Education and Background, I have a Bachelor’s in Science with a Major in Biochemistry and a Minor in Immunology, a Ph.D. in Science/Genetics, did my Post-Doctoral Degree in Molecular Genetics at Harvard University in Boston, MA and an MBA in Entrepreneurship at the Start Up Health Academy in New York, NY. I have contributed extensively to Academic Research with more than seventy-five peer-reviewed articles and white papers, from which five were the in Cover of the Journals. I have also published two book chapters and a US Patent. As an Entrepreneur, I founded one consultancy company and cofounded two big data analytics companies in the healthcare and biotechnology sectors. In one of these big data analytics companies I was the CEO, CSO (Chief Scientific Officer) and we have raised Seed, Angel and Round A Venture Capital (VC) Money. In the position of DataGenno’s CEO, I was able to increase our client’s revenues more than 10X in only 6 months. This company was sold in 2016. My background in Entrepreneurship goes from building a Start Up from the ground up, developing a Solution, getting an IP (Patent), getting Venture Capital Investment and exiting the company with a 5X ROI having the entrepreneur/inventor experience from beginning to end. As an Innovator and Serial Entrepreneur, I have also become a Member and Mentor in more than fifteen Life Sciences, Technology and Healthcare Start Up Company Incubators, Accelerators and TTOs globally (United States, Europe, Asia and South America). In addition, I became a Project Manager (PM) of Apple's (NASDAQ:AAPL) International Training Program and a Member at both Google’s (NASDAQ:GOOG) for Entrepreneurs & High Education Programs. Recently, I became a Member of the Singularity University (SU) Hub through their Exponential Innovation Program.

Brady Davis

Brady Davis
Vice President, Strategy and Markeing
DNAnexus
Brady Davis
Vice President, Strategy and Markeing
DNAnexus
 
About Speaker:

Brady brings over 15 years experience as an innovator and leader in the life sciences space as well as the hospital ACO and consumer health and wellness industries. Prior to DNAnexus, Brady was head of strategy and market development for Illumina with a special focus on Informatics and driving opportunities to use genetics data as clinical utility. Brady serves on the board of multiple non-profit organizations including the Global Alzheimer's Association Interactive Network (GAAIN), Cancer Commons, Ci4CC, and is Co-Chair of the Advisory Board for the University of Washington Center for Commercialization (C4C). Brady is a graduate of University of Washington.

Ted Driscoll

Ted Driscoll
Managing Partner
DigitalDx Ventures
Ted Driscoll
Managing Partner
DigitalDx Ventures
 
About Speaker:

Dr. Ted Driscoll is starting a new venture fund named DigitalDx Ventures, focused on personalized, big-data diagnostics. Dr. Driscoll was previously a Partner at Claremont Creek Ventures leading its efforts in Digital Healthcare and Diagnostics. He led the first investments in Natera (IPOed in 2015), AssureX Health (acquired by Myriad Genetics for $410M) and GeneWeave Biosciences (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader or founder of five startups. His first startup, International Imaging Systems, pioneered the first Digital Subtractive Angiography machines. He then led the technical team at Identix that pioneered the first digital fingerprint recognition which is now used in devices such as the iPhone. Identix went public in 1984. At his next startup, Diasonics, he led the team that created the world’s first MRI scanners, as Senior VP of Engineering and R&D. He was then named Division President of a spinoff from Diasonics named Focus Surgery that pioneered noninvasive HIFU ablation surgery. This company was then purchased by Takai Hospital Supply. His last startup was Be Here Technologies, a 360degree imaging company. This technology was purchased by and incorporated into Google Streetview. During his startup experience he was the inventor of over 50 patents. He graduated from Stanford with a Ph.D. in Digital Imaging, and previously received a Masters in Computer Graphics from Harvard, and a BA from the University of Pennsylvania.

Terry Gaasterland

Terry Gaasterland
Professor and Director of Scripps Genome Center
UCSD
Terry Gaasterland
Professor and Director of Scripps Genome Center
UCSD
 
About Speaker:

Dr. Gaasterland leads a research program aimed to develop and apply methods to identify genes and the impact of their genetic and evolutionary variation on regulation of transcription and on protein domain structure and function.  Dr. Gaasterland has extensive experience with microbial genome sequencing and annotation, use of RNA-seq data to identify genes in assembled genomes from novel organisms, software tools to detect horizontally transferred genes in microbes, the management and analysis of large next-generation high-throughput sequencing datasets, and the sequencing and analysis of marine microbial, eukaryotic, and human genomes. Accomplishments in these areas as well as her early career work in deductive databases is reflected in over 100 refereed publications. Dr. Gaasterland trained as a computer scientist with emphasis in databases, automated reasoning and reasoning with uncertain information. With a Department of Energy postdoctoral fellowship, she transitioned from pure computer science into the application of methods in databases and artificial intelligence to the interpretation and analysis of genomic sequence and gene expression data. Since receiving the Presidential Early Career Award in Science and Engineering (PECASE) in 2000, she has been continuously funded by the National Science Foundation to develop and use methods in computational genomics, and has participated as PI or co-PI on a series of biomedical grants from the NIH. She is PI of NIH/NEI awards to sequence and analyze variation in protein coding exons genome-wide for 400 primary open angle glaucoma cases, as a member of the NEIGHBOR Consortium at the Massachusetts Eye and Ear Institute and the NHGRI Medical Sequencing program.

Mark Kunitomi

Mark Kunitomi
Research Staff Member, Industrial and Applied Genomics
IBM
Mark Kunitomi
Research Staff Member, Industrial and Applied Genomics
IBM
 
About Speaker:

Dr. Kunitomi is a Research Staff Member at IBM Research. His research is focused on understanding how big data analytics and machine learning can be applied to bacterial genomics in order to design rapid diagnostics, characterize metagenomic samples, learning how Antimicrobial Resistance develops, and predicting novel therapeutics.

Sean Scott

Sean Scott
Chief Business Officer & VP of Market Development
QIAGEN Bioinformatics
Sean Scott
Chief Business Officer & VP of Market Development
QIAGEN Bioinformatics
 
About Speaker:

Sean P. Scott is the Chief Business Officer and VP, Market Development for QIAGEN’s Clinical Genomics and Bioinformatics business area. In this role Sean leads QIAGEN’s efforts to identify, develop and commercialize dry lab solutions with molecular diagnostics and molecular pathology testing laboratories to design, develop and scale NGS-based genetic tests. Sean recently led the development of QIAGEN new Clinical Insights decision support platform for screening, diagnostic, theranostic and prognostic testing across inherited-germline and somatic indications. Sean joined QIAGEN in 2013 through QIAGEN’s acquisition of Ingenuity Systems where he was Ingenuity’s SVP, Global Commercial Operations and SVP, Corporate Development.  Sean has spent the past decade working with Pharma and Clinical customers on their challenges associated with the interpretation of genomics data and integrated genomics data into precision medicine based practices.

Asim Siddiqui

Asim Siddiqui
Chief Technology Officer
Numedii
Asim Siddiqui
Chief Technology Officer
Numedii
 
About Speaker:

Dr. Siddiqui has over 20 years of experience in bioinformatics and software engineering. Prior to joining NuMedii as Chief Technology Officer, he served as Vice President of Product Development at Natera where he built Natera’s product management and program management functions. Dr. Siddiqui drove improvements to Natera’s NIPT diagnostic including its cloud strategy and cell free cancer program. Prior to that, he served as the Director of Bioinformatics at Life Technologies where he was awarded the Life Technology Inventor Award for his work on NGS bioinformatics. He spent several years at the BC Cancer Agency as Bioinformatics Group Leader involved in large scale genomic projects and leading standards creation. He is an author on over 30 peer-reviewed publications. He holds a doctorate in Bioinformatics from Oxford University and a bachelor’s degree in Physics from Cambridge University.

Ratna Thangudu

Ratna Thangudu
Project Manager
ESAC Inc.
Ratna Thangudu
Project Manager
ESAC Inc.
 
About Speaker:

Dr Thangudu is the Project Manager for the NCI's Proteomic Data Commons. He has also been supporting the NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC)'s data coordinating center during the phase II and the ongoing phase III efforts. He also provided subject matter expertise to the NIH BD2K Standards Coordinating Center.

Bart Vannieuwenhuyse

Bart Vannieuwenhuyse
Senior Director, Health Information Sciences
Janssen R&D
Bart Vannieuwenhuyse
Senior Director, Health Information Sciences
Janssen R&D
 
About Speaker:
Ray Veeraraghavan

Ray Veeraraghavan
Director of IT & Informatics
Rady Children’s Institute for Genomic Medicine
Ray Veeraraghavan
Director of IT & Informatics
Rady Children’s Institute for Genomic Medicine
 
About Speaker:

Narayanan “Ray” Veeraraghavan, PhD, is the Director of Informatics & IT at Rady Children’s Institute for Genomic Medicine, heading the bioinformatics, information management and IT infrastructure efforts at the Institute.

Previously, Ray led the CAP/CLIA compliant clinical bioinformatics enterprise at Baylor College of Medicine, at its Human Genome Sequencing Center (research) and the Whole Genome Laboratory (commercial) units. During this time, Ray also led the largest ever biomedical compute on Amazon cloud (AWS), for the CHARGE consortium – a 10+ site consortium focused on identifying biomarkers that influence risk in many heart and aging related diseases. This work won the BioIT- World award in 2014 and was (is) also highlighted by AWS as a case-study for efficient ultra-large scale collaborative genomic analyses.

Before joining RCIGM, Ray was a co-investigator in many NIH funded clinical next-gen sequencing based grants such as the Undiagnosed Disease Network (UDN) and eMERGE, and has provided his expertise on FDA panels for bioinformatic metrics and vendor evaluation in genomic medicine.

Ray earned his PhD in Chemical Biology (Penn State), a MS in Industrial Engineering (Penn State) and a BS in Mechanical Engineering (Mumbai, India). He has been able to leverage his engineering background, scientific training and software industry experience in the multitude of projects over the last 17+ years.